Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Blinded Drug

7 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Prevention

    VICCPED1627

    11/17/2016

    Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis

    Prevention

    COGALTE1621

    10/03/2016

    Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

    Supportive Care

    VICCBMT1610

    09/30/2016

    A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

    Treatment

    VICCTHO15115

    11/08/2016

    A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120 Mg Plus Bsc Vs. Placebo Plus Bsc For Tumor Control In Subjects With Well Differentiated, Metastatic And/Or Unresectable Typical Or Atypical Lung Neuroendocrine Tumors

    Treatment

    VICCHN1574

    03/21/2016

    A Randomized, Multicenter, Double-Blind Phase 2 Study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus -Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen

    Treatment

    VICCBRE1692

    09/01/2015

    Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

    Treatment

    VICCSAR1483

    02/26/2015

    SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas


    Print this page for your doctor